Eli Lilly (NYSE: LLY) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and rising patient volumes can generate durable earnings sufficient to overcome pricing
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.